Liquidia Corp is a biopharmaceutical firm based in Morrisville, North Carolina, focusing on creating innovative treatments for patients with unmet medical needs. Its flagship product, YUTREPIA, is an inhaled dry powder version of treprostinil designed to address pulmonary arterial hypertension. Additionally, the company offers a generic treprostinil injection, expanding its impact on patient care. Founded in 2004, Liquidia continues to pioneer in the healthcare sector, aiming to improve quality of life through advanced medical solutions.